Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Development Should Target “Residual Uncertainty,” FDA Says

Executive Summary

Agency officials stress their willingness to work with applicants, while an industry expert urges comparative testing in the setting or settings most sensitive to potential differences.

You may also be interested in...



Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff

Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.

Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade

Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.

Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade

Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel